ROCHE-WV16241

Study Sponsor : Roche

Study Title

A phase III partially double blinded study evaluating the efficacy and safety of 4okD branched pegylated inteferon alfa-2a (PEG-IGFN, Ro 25-8310) combined with placebo or lamivudine versus lamivudine in anti-HBe positive patients with chronic hepatitis B

Medicine or Vaccine (generic name)

peg-interferon alpha-2a

Sponsor Identification Number

WV16241

Trial Registry Identification Number(#'s)

Medical Condition

chronic hepatitis b

Phase

Phase 3

Link to study details on the Roche Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

January 2014